Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

This grant opportunity is designed to support the development of biomarkers or biomarker signatures for neurological and neuromuscular disorders. It encourages initial discovery and evaluation of potential biomarkers that could be utilized to streamline the clinical development of neurotherapeutic treatments and their application in clinical practice. While this grant supports animal studies, it notably requires preliminary human evaluation using standardized human samples or datasets.

The primary aim of this Funding Opportunity Announcement (FOA) is to support efforts in identifying and initiating the biological, analytical, and clinical assessment of prospective biomarkers for neurological and neuromuscular conditions. Through this initiative, the goal is to generate potential biomarkers or biomarker signatures that are equipped for comprehensive analytical and clinical verification studies. This grant is open to clinical trials, but they are not mandatory, as indicated by the "R61/R33 Clinical Trial Optional" title.